TMCnet News
R-Tech Ueno: Announcement of Initiation of the Phase I Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096TOKYO --(Business Wire)-- R-Tech Ueno (JASDAQ: 4573): We are pleased to announce that as of today, the company has started the phase one clinical trial for the new molecular entity RTU-1096, which is a vascular adhesion protein-1 (VAP-1) inhibitor having anti-inflammatory and immunomodulatory effects. The descriptions are as follows: The company has developed the anti-inflammatory drug with a new mechanism of action based on the VAP-1 inhibitory effect. At present, the company has started the phase I clinical trial for the oral agent of a new molecular entity (Development Code: RTU-1096) targeted at healthy male adults. This trial is intended to examine the safety, tolerability, and pharmacokinetics of the inhibitor with a single dose. The trial would be conducted as placebo-controlled, double-blind, dose-escalation study complied with the Good Clinical Practice (GCP).
Dr. Yukihiko Majima, President of the company, has stated as follows: The above venture will not contribute to any revision of the full-year earnings estimates pre-announced on May 14, 2014.
For full details of the press release, please visit:
|